- Home
- VTAK vs XXII Comparison
VTAK vs XXII Comparison
Compare VTAK & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- XXII
- Stock Information
- Founded
- VTAK 2002
- XXII 1998
- Country
- VTAK United States
- XXII United States
- Employees
- VTAK N/A
- XXII N/A
- Industry
- VTAK Medical/Dental Instruments
- XXII Medicinal Chemicals and Botanical Products
- Sector
- VTAK Health Care
- XXII Health Care
- Exchange
- VTAK Nasdaq
- XXII Nasdaq
- Market Cap
- VTAK 3.1M
- XXII 2.8M
- IPO Year
- VTAK 2018
- XXII N/A
- Fundamental
- Price
- VTAK $0.35
- XXII $3.15
- Analyst Decision
- VTAK
- XXII
- Analyst Count
- VTAK 0
- XXII 0
- Target Price
- VTAK N/A
- XXII N/A
- AVG Volume (30 Days)
- VTAK 149.8K
- XXII 166.3K
- Earning Date
- VTAK 03-31-2025
- XXII 03-27-2025
- Dividend Yield
- VTAK N/A
- XXII N/A
- EPS Growth
- VTAK N/A
- XXII N/A
- EPS
- VTAK N/A
- XXII N/A
- Revenue
- VTAK $399,000.00
- XXII $17,304,000.00
- Revenue This Year
- VTAK $38.46
- XXII $56.94
- Revenue Next Year
- VTAK $533.33
- XXII $2.98
- P/E Ratio
- VTAK N/A
- XXII N/A
- Revenue Growth
- VTAK 27.07
- XXII N/A
- 52 Week Low
- VTAK $0.31
- XXII $3.01
- 52 Week High
- VTAK $4.10
- XXII $581.85
- Technical
- Relative Strength Index (RSI)
- VTAK 34.81
- XXII 35.94
- Support Level
- VTAK $0.33
- XXII $3.01
- Resistance Level
- VTAK $0.43
- XXII $3.47
- Average True Range (ATR)
- VTAK 0.03
- XXII 0.33
- MACD
- VTAK -0.00
- XXII 0.11
- Stochastic Oscillator
- VTAK 17.00
- XXII 11.29
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.